Last reviewed · How we verify
A Single Center, Prospective Study Evaluating the Anti-fibrotic Effect of Combination Therapy of Peginterferon Alpha-2a Plus Ribavirin in Patients with Chronic Hepatitis C, Based on Histologic Changes and Noninvasive Fibrosis Assessments
•The purpose of this study is to compare the performance between liver biopsy and non-invasive fibrosis assessments evaluating anti-fibrotic efficacy of peginterferon plus ribavirin in patients with hepatitis C pre- and post-treatment
Details
| Lead sponsor | Seoul National University Boramae Hospital |
|---|---|
| Status | COMPLETED |
| Enrolment | 55 |
| Start date | 2012-07 |
| Completion | 2018-02-09 |
Conditions
- Chronic Hepatitis C
Interventions
- chronic hepatitis C
Primary outcomes
- Anti-fibrotic response — 48 weeks after the end of treatment
Anti-fibrotic response, indicated by a lack of histological worsening, defined as the stabilization or the improvement of at least one stage in the histologic fibrosis staging 48 weeks after the end of treatment
Countries
South Korea